| White, Julia R |
rtog 1005, NCT01349322: Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery |
|
|
| Active, not recruiting | 3 | 2354 | Europe, Canada, Japan, US, RoW | Standard fractionation whole breast irradiation, three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), Hypofractionated whole breast irradiation, Concurrent boost, Sequential boost | Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology | Breast Cancer | 01/22 | | | |
OSU-13282, NCT02186470: Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients with Hormone Responsive Stage 0-I Breast Cancer |
|
|
| Active, not recruiting | N/A | 22 | US | accelerated partial breast irradiation, APBI, intensity-modulated radiation therapy, IMRT, image-guided radiation therapy, therapeutic conventional surgery | Ohio State University Comprehensive Cancer Center | Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma with Predominant Intraductal Component, Medullary Ductal Breast Carcinoma with Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Tubular Ductal Breast Carcinoma | 03/25 | 03/25 | | |
NCT03976154: Effects of Fixation Technique On Thoracic Epidural Catheter Displacement |
|
|
| Recruiting | N/A | 300 | US | Thoracic Epidural Catheter Fixation Techniques | University of Utah | Thoracic Epidural | 08/24 | 08/24 | | |
| Recruiting | N/A | 3000 | US | Treatment Recommendation Surveys, 7-gene biosignature | PreludeDx, University of South Florida | DCIS | 12/25 | 12/35 | | |
| Jackson, Christopher G |
COMPASS, NCT05371613 / 2021-005200-35: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) Vs Idursulfase in Pediatric and Young Adult Participants with Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) |
|
|
| Recruiting | 2/3 | 54 | Europe, Canada, US, RoW | tividenofusp alfa, idursulfase | Denali Therapeutics Inc. | Mucopolysaccharidosis II | 12/25 | 12/25 | | |
| Recruiting | 2 | 15 | Europe, Canada, US, RoW | Inebilizumab | Amgen, Horizon Therapeutics Ireland DAC | Neuromyelitis Optica Spectrum Disorder | 04/27 | 04/27 | | |
OTC-HOPE, NCT06255782: An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency |
|
|
| Recruiting | 1/2 | 13 | Europe, US, RoW | ECUR-506 | iECURE, Inc. | Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn | 09/26 | 09/26 | | |
| Active, not recruiting | 1 | 24 | Europe, Canada, US, RoW | Radiprodil | GRIN Therapeutics, Inc., GRIN Therapeutics, Inc. | GRIN-related Disorders | 11/26 | 11/26 | | |
NCT06805695: Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP) |
|
|
| Recruiting | N/A | 13 | Europe | No Intervention | iECURE, Inc. | Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Urea Cycle Disorders, Inborn | 07/41 | 07/41 | | |
| Peterson, Kathryn A |
| Active, not recruiting | 2 | 41 | US | Dupilumab (blinded), Placebo (blinded), Dupilumab (open-label) | Children's Hospital Medical Center, Cincinnati, Regeneron Pharmaceuticals, National Institutes of Health (NIH) | Eosinophilic Gastritis, Eosinophilic Gastroenteritis | 03/24 | 11/24 | | |
| Recruiting | N/A | 30 | US | | Children's Hospital Medical Center, Cincinnati | Eosinophilic Gastritis, Gastroparesis, Gastric Motility Disorder | 05/25 | 06/25 | | |
NCT02523118: OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages |
|
|
| Recruiting | N/A | 1350 | US | | Children's Hospital Medical Center, Cincinnati, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), ORDR, National Center for Advancing Translational Sciences (NCATS) | Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis | 12/50 | 01/51 | | |
| Hopf, Harriet W |
NCT03976154: Effects of Fixation Technique On Thoracic Epidural Catheter Displacement |
|
|
| Recruiting | N/A | 300 | US | Thoracic Epidural Catheter Fixation Techniques | University of Utah | Thoracic Epidural | 08/24 | 08/24 | | |
| Chan, Gary M |
NCT03356652: Electrical Activation Mapping Guided Tailor Made Approach for Cardiac Resynchronization Therapy |
|
|
| Recruiting | N/A | 93 | RoW | Noninvasive electrical dyssynchrony study, Noninvasive electrical activation, Electrical Activation Mapping, Noninvasive mapping system, ECVUE | Chinese University of Hong Kong | Heart Failure | 08/24 | 08/24 | | |
| Shihab, Fuad |
KOAR, NCT03326076: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry |
|
|
| Active, not recruiting | N/A | 4000 | US | Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox) | CareDx | Kidney Transplant Rejection | 06/25 | 12/25 | | |
| Active, not recruiting | N/A | 5000 | US | Prospera | Natera, Inc., University of Maryland | Kidney Transplant Rejection | 10/26 | 10/27 | | |
| Scholand, Mary Beth |
| Active, not recruiting | 4 | 70 | US | Nintedanib, OFEV, Placebo, Standard of Care | Rohit Aggarwal, MD, Boehringer Ingelheim | Myositis Associated Interstitial Lund Disease (MA-ILD) | 07/25 | 12/25 | | |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 576 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 06/25 | 06/25 | | |
|
|
| Active, not recruiting | 3 | 202 | US | N-acetyl cysteine, NAC, Placebo | Weill Medical College of Cornell University, University of Virginia, University of Michigan, Pulmonary Fibrosis Foundation, University of Washington, National Heart, Lung, and Blood Institute (NHLBI), Three Lakes Foundation | Idiopathic Pulmonary Fibrosis | 02/26 | 02/26 | | |
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 698 | Canada, US, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | 11/27 | 11/27 | | |
| Completed | 2 | 80 | Europe, US | Orvepitant Maleate, Placebo | Nerre Therapeutics Ltd., Pharm-Olam International | Cough, Idiopathic Pulmonary Fibrosis | 06/24 | 06/24 | | |
| Recruiting | N/A | 135 | US | | National Jewish Health, University of California, Davis, Mayo Clinic, University of Chicago, University of Texas Southwestern Medical Center, University of Arizona, University of Utah | Hypersensitivity Pneumonitis | 01/25 | 01/26 | | |
| Dibble, Lee |
SuBTyPE, NCT06381674: Wearable Technology to Characterize and Treat mTBI Subtypes: Biofeedback-Based Precision Rehabilitation |
|
|
| Recruiting | N/A | 100 | US | Vestibular therapy for mTBI augmented with audio and visual real-time biofeedback, Rehabilitation, Vestibular therapy for mTBI | Oregon Health and Science University, United States Department of Defense | Mild Traumatic Brain Injury, Concussion, Rehabilitation, Balance Impairment | 09/28 | 09/28 | | |
| Recruiting | N/A | 370 | Canada, US | Treadmill walking | Northwestern University, University of Pittsburgh, The Parkinson Study Group | Parkinson Disease | 07/27 | 07/28 | | |
| Turok, David |
NCT06162611: Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo |
|
|
| Recruiting | 4 | 790 | US | Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg, Etonogestrel implant with oral placebo | Lori Gawron, Planned Parenthood Association of Utah | Emergency Contraception | 01/28 | 05/28 | | |
NCT05444582: Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start |
|
|
| Recruiting | 4 | 1404 | US | Levonorgestrel 52 MG Intrauterine System | University of Utah, Planned Parenthood Federation of America | Contraception | 03/27 | 07/27 | | |
NCT03633799: Evaluation of Efficacy, Safety and Tolerability of VeraCept IUD |
|
|
| Active, not recruiting | 3 | 1620 | US | VeraCept | Sebela Women's Health Inc., Synteract, Inc. | Women at Risk for Pregnancy | 09/22 | 09/27 | | |
NCT05342974: Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy |
|
|
| Active, not recruiting | 1 | 9 | US | Atorvastatin, Misoprostol | University of Utah, Grand Challenges Canada | Abortion Early | 12/23 | 12/24 | | |
| Recruiting | N/A | 656 | US | Ovaprene | Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Contraception | 06/25 | 09/25 | | |
| Active, not recruiting | N/A | 1030 | US | Copper T-380 IUD, Paragard IUD, LNG IUD, Mirena IUD, Skyla IUD, Contraceptive implant Nexplanon, Etonorgestrel contraceptive implant, Implanon, Nexplanon, Depo-Provera, Depo, Intramuscular medroxyprogesterone acetate | University of Utah | IUD, Contraceptive Implant, Contraception, Birth Control, Emergency Contraception | 01/25 | 01/26 | | |
| Majersik, Jennifer |
CREST-H, NCT03121209: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics |
|
|
| Active, not recruiting | 3 | 385 | Canada, US | Revascularization, Intensive Medical Management (IMM) alone | Columbia University, National Institute of Neurological Disorders and Stroke (NINDS), Mayo Clinic, University of Alabama at Birmingham, University of Maryland, University of California, Los Angeles | Internal Carotid Artery Stenosis, Cognitive Impairment | 01/27 | 07/27 | | |
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
|
|
| Recruiting | 3 | 1683 | US | Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management | University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca | Intracranial Arteriosclerosis, Stroke | 05/28 | 05/28 | | |
| Active, not recruiting | 1 | 20 | US | Memantine XR, Namenda XR, Placebo (for memantine), sugar capsule | University of Utah | Ischemic Stroke, Upper Extremity Weakness | 05/25 | 05/25 | | |
CREST-2, NCT02089217: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial |
|
|
| Active, not recruiting | N/A | 2486 | Europe, Canada, US, RoW | Carotid endarterectomy (CEA), Carotid Stenting (CAS), Intensive Medical Management - no CEA, Intensive Medical Management - no CAS | Thomas G. Brott, M.D., National Institute of Neurological Disorders and Stroke (NINDS) | Carotid Stenosis | 02/26 | 02/26 | | |
VERIFY, NCT05338697: Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials |
|
|
| Recruiting | N/A | 657 | US | Transcranial Magnetic Stimulation (TMS) | University of Cincinnati, University of California, Los Angeles, University of Auckland, New Zealand, Medical University of South Carolina | Stroke, Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic | 01/27 | 01/27 | | |
| Recruiting | N/A | 400 | US | ReStoreD | University of Utah | Stroke, Depression, Anxiety, Coping Skills, Couples | 08/26 | 08/27 | | |
| Recruiting | N/A | 8000 | US | | Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS) | Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment | 11/25 | 11/25 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy |
|
|
| Recruiting | 4 | 100 | US | Ketamine | University of Oklahoma | Hemorrhoids | 01/25 | 07/25 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 09/25 | 12/25 | | |
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients |
|
|
| Not yet recruiting | 4 | 100 | US | Skin Cleanser Combination No.1 | Boston Children's Hospital | Atopic Dermatitis | 12/28 | 12/28 | | |
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction |
|
|
| Not yet recruiting | 4 | 40 | US | fentanyl and Remimazolam | Indiana University, Indiana University Health | Dental Extraction | 01/26 | 03/26 | | |
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin |
|
|
| Terminated | 4 | 109 | US | Tamsulosin Hydrochloride | University of Massachusetts, Worcester, UMass Memorial Health Care | Thoracic Diseases, Urinary Retention | 10/23 | 10/23 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC |
|
|
| Not yet recruiting | 3 | 632 | RoW | docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy | Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location |
|
|
| Recruiting | 3 | 50 | US | Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol | Planned Parenthood League of Massachusetts | Abortion | 07/24 | 09/24 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Not yet recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 166 | US | TheraBionic Device, Placebo Device, Quality of Life Assessment | THERABIONIC INC., National Cancer Institute (NCI) | Hepatocellular Carcinoma | 10/24 | 10/24 | | |
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, abiprubart, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 65 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 520 | Europe, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Recurrent or Metastatic Solid Tumors | 07/28 | 07/28 | | |
MAST, NCT06355583: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant () Trial |
|
|
| Not yet recruiting | 2 | 50 | Europe | EBX-102, IMT capsules, Placebo | Imperial College London | Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia | 02/26 | 05/27 | | |
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 100 | RoW | Tis-U-Sol | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Union hospital of Fujian Medical University, Zhujiang Hospital, Guangdong Provincial People's Hospital | Nasopharyngeal Neoplasms | 05/24 | 05/26 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
| Recruiting | 2 | 32 | RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 06/25 | 10/25 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo |
|
|
| Recruiting | 2 | 120 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 08/25 | 01/26 | | |
NCT05029336: Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases |
|
|
| Recruiting | 2 | 20 | US | Depletion of CD3/CD19 in an autologous stem cell transplant, CD3/CD19 depletion using cliniMACs device | Stephan Grupp MD PhD | Systemic Lupus Erythematosus, Systemic Sclerosis | 12/26 | 05/31 | | |
| Recruiting | 2 | 64 | US | Bevonescein, ALM-488 | Alume Biosciences, Inc. | Surgery, Nerve Injury, Imaging | 06/25 | 09/25 | | |
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) |
|
|
| Withdrawn | 2 | 25 | RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Freezing of Gait Symptoms in Parkinson's Disease | 12/24 | 03/25 | | |
| Not yet recruiting | 2 | 200 | Japan, US | Raludotatug deruxtecan, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Metastatic Solid Tumors | 09/27 | 09/27 | | |
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
|
|
| Recruiting | 2 | 240 | US | COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1 | GeoVax, Inc., National Cancer Institute (NCI) | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | 12/26 | 12/27 | | |
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, -study |
|
|
| Not yet recruiting | 2 | 26 | Europe | TCP-25 gel, Vehicle (placebo) | Xinnate AB | Epidermolysis Bullosa (EB) | 06/26 | 06/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 06/26 | 06/26 | | |
| Recruiting | 1/2 | 55 | Europe | CR6086, vorbipiprant, AGEN2034, balstilimab | Rottapharm Biotech, Agenus Inc. | Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic GI Cancers, Gastric Cancer | 03/25 | 09/26 | | |
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus |
|
|
| Active, not recruiting | 1/2 | 26 | US | DS-7011a, Placebo | Daiichi Sankyo | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
| Active, not recruiting | 1/2 | 190 | Europe, US | ASTX029 | Taiho Oncology, Inc. | Solid Tumor, Adult | 08/24 | 12/25 | | |
NCT05979831: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome |
|
|
| Active, not recruiting | 1/2 | 9 | Europe | DS-2325a, Placebo | Daiichi Sankyo | Netherton Syndrome | 01/25 | 01/25 | | |
IDeate-Lung03, NCT06362252: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 123 | Europe, Japan, US | Ifinatamab deruxtecan, I-DXd, Atezolizumab, Carboplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive Stage-small Cell Lung Cancer | 09/26 | 12/26 | | |
| Recruiting | 1/2 | 145 | US, RoW | SQ3370 | Shasqi, Inc. | Cancer | 08/24 | 07/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/25 | 03/27 | | |
|
| Active, not recruiting | 1/2 | 666 | Europe, Canada, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™ | Genmab, AbbVie | DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) | 03/25 | 01/29 | | |
|
|
|
|
|
|
|
|
|
|
|
| Not yet recruiting | 1/2 | 42 | US | RXRG001, Placebo | RiboX Therapeutics Ltd. | Radiation-Induced Xerostomia and Hyposalivation | 08/27 | 08/27 | | |
NCT05693025: Evaluation of the Walk With Ease Program for Fall Prevention |
|
|
| Recruiting | 1/2 | 240 | US | Group Exercise, Behavioral Training | Iowa State University | Exercise, Frailty, Arthritis, Accidental Falls | 05/25 | 05/26 | | |
| Recruiting | 1/2 | 470 | Europe, Japan, US | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 07/27 | | |
